Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study
Journal of Cellular and Molecular Medicine · 2024-03 · 28 (5)
DOI: 10.1111/jcmm.18008 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 27.10.2023. Verfasst von Shuochuan Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, …. Hauptthemen laut MEDLINE: Quinolines, Breast Neoplasms, Indoles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Shanghai Municipality, Project of Henan Provincial Health Commission.
Abstract (Originalsprache)
Anlotinib, a multitarget tyrosine kinase inhibitor, can inhibit tumour angiogenesis proliferation, metastasis, promote vascular normalization, increase T cell and NK cell activity and infiltration, remodel tumour microenvironment and synergistic immune enhancement. Our study aimes to evaluate the efficacy of anlotinib in the treatment of advanced metastatic breast cancer (MBC) after multiple lines of therapy. Patients included were treated with anlotinib for advanced MBC in the Affiliated Cancer Hospital of Zhengzhou University from 1 January 2019 to 30 June 2023. The objective remission rate, disease‐free progression survival and adverse reactions were analysed. We compared and analysed the efficacy of anlotinib in the treatment of advanced metastatic breast cancer, which showed that ORR was 23.6% and DCR was 69.1%. The DCR of monotherapy was 66.7% and that of combination therapy was 69.6% in MBC patients. The combination therapy, combined with chemotherapy had the best effect (79.3%), combined with immunotherapy came second. In addition, the DCR (88.9%) was higher in MBC patients having received prior antiangiogenic therapy. According to the Kaplan–Meier (K‐M) survival estimate analysis, the mPFS was 4.17 months (95% CI, 1.758–6.582 months) in Her‐2 positive MBC patients, and 7.83 months (95% CI, 2.416–9.104) in Her‐2 negative MBC patients. The mPFS was 5.76 months (95% CI, 3.231–8.298 m) in HR positive MBC patients, 7.83 months (95% CI, 3.182–12.478 m) in TNBC patients. Fatigue (20.0%), hypertension (21.8%) and liver dysfunction (18.2%) were common adverse reactions, followed by bone marrow suppression (16.4%), anorexia (14.5%), hypothyroidism (14.5%) and diarrhoea (14.5%). Altogether, Anlotinib monotherapy or combination therapy provides a viable third (or above)‐line therapeutic strategy in patients with metastatic breast cancer. The adverse reactions of anlotinib are well tolerated and controllable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast disease, Henan Breast Cancer Center, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan Province, China.
- Deprtment of Ultrasonography, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Combine Traditional Chinese & Western, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan Province, China.
ORCID-Profile: Lu Zhang
Förderung
- Natural Science Foundation of Shanghai Municipality
- Project of Henan Provincial Health Commission
Zitieren
APA
Liu, S., Zhi, W., & Zhang, L. (2024). Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study. Journal of Cellular and Molecular Medicine, 28(5). https://doi.org/10.1111/jcmm.18008
Vancouver
Liu S, Zhi W, Zhang L. Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study. Journal of Cellular and Molecular Medicine. 2024;28(5). doi:10.1111/jcmm.18008
BibTeX
@article{Liu2024,
author = {Liu, Shuochuan and Zhi, Wenxiang and Zhang, Lu},
title = {Efficacy of anlotinib in Chinese patients with metastatic breast cancer: A retrospective observational study},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
volume = {28},
number = {5},
doi = {10.1111/jcmm.18008}
}
EUVIMED